 European Medicines Agencys advisory committee issued a positive opinion recommending the approval of Myovant Sciences Ltds NYSE: MYOV Ryeqo relugolix, estradiol, and norethindrone acetate for uterine fibroids. The final decision on the application is expected to be available in approximately two months. 